Alkermes (ALKS) Shares Outstanding (2010 - 2026)
Alkermes' (ALKS) quarterly Shares Outstanding (Entity) came in at $183.6 million in Q1 2026, up 1.89% year-on-year from $180.2 million in Q1 2025, and up 1.43% on a QoQ basis from $181.0 million in Q4 2025.
Alkermes (ALKS) Shares Outstanding (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Shares Outstanding (Entity) data on file, last reported at $183.6 million in Q1 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 1.89% year-over-year to $183.6 million in Q1 2026; TTM through Mar 2026 was $183.6 million, a 1.89% increase from a year earlier, with the FY2025 full-year figure at $181.0 million, up 2.46% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $183.6 million, up from $181.0 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for ALKS reached as high as $183.6 million in Q1 2026 and fell as low as $167.7 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $174.9 million across 5 years, with a median of $175.7 million in 2024.
- Across the five-year window, Shares Outstanding (Entity) rose 1.89% in 2023 and increased 2.55% in 2025, its largest moves.
- Year by year, Shares Outstanding (Entity) stood at $169.0 million in 2022, then climbed by 2.14% to $172.6 million in 2023, then rose by 2.38% to $176.7 million in 2024, then increased by 2.46% to $181.0 million in 2025, then grew by 1.43% to $183.6 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $183.6 million in Q1 2026, $181.0 million in Q4 2025, and $180.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 43.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 31.59 Bn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | 166.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166.20 Mn |
| Dec 31, 2025 | 164.70 Mn |
| Sep 30, 2025 | 165.09 Mn |
| Jun 30, 2025 | 164.96 Mn |
| Mar 31, 2025 | 163.41 Mn |
| Dec 31, 2024 | 165.39 Mn |
| Sep 30, 2024 | 163.37 Mn |
| Jun 30, 2024 | 168.32 Mn |
| Mar 31, 2024 | 167.98 Mn |
| Dec 31, 2023 | 166.22 Mn |
| Sep 30, 2023 | 166.61 Mn |
| Jun 30, 2023 | 166.28 Mn |
| Mar 31, 2023 | 165.09 Mn |
| Dec 31, 2022 | 163.54 Mn |
| Sep 30, 2022 | 164.28 Mn |
| Jun 30, 2022 | 163.84 Mn |
| Mar 31, 2022 | 162.48 Mn |
| Dec 31, 2021 | 160.94 Mn |
| Sep 30, 2021 | 161.46 Mn |
| Jun 30, 2021 | 160.82 Mn |